PT-141 peptide for men near me: prescribers, legality, and how it works

Last updated 2026-07-24

What is PT-141 and is it approved for men?

PT-141 is the shorthand for bremelanotide, a synthetic heptapeptide that activates melanocortin receptors MC3R and MC4R in the central nervous system ^[1]. The FDA approved bremelanotide as Vyleesi in June 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women ^[2]. That's the only approved indication. For men, bremelanotide has no FDA-approved product and no completed Phase 3 trials published in peer-reviewed journals. Early-phase studies in men exist (some dating to 2006 and 2007), but the sponsor did not pursue male approval ^[3]. Any use in men is therefore off-label, prescribed at physician discretion under the same legal framework that allows any approved drug to be prescribed for non-approved indications ^[4]. Off-label prescribing is legal and common (roughly 20 percent of all prescriptions in the U.S. are off-label), but it means you and your prescriber are operating on thinner evidence and no regulatory review for safety or efficacy in the population ^[4].

How does PT-141 work in the brain?

Bremelanotide is a melanocortin receptor agonist. It binds MC3R and MC4R, which are concentrated in the paraventricular nucleus and other hypothalamic nuclei involved in sexual motivation ^[1][5]. This central mechanism is what sets bremelanotide apart from PDE5 inhibitors like sildenafil (Viagra), which work on vascular smooth muscle and have no direct effect on desire ^[6]. In animal models, melanocortin receptor activation increased mounting behavior, grooming, and measures of arousal ^[7]. In humans, the neurobiology is less well-mapped. The approved trial in women measured changes in desire and distress scores, not brain activity directly, but the working model is that MC4R activation in the hypothalamus modulates dopamine and other neurotransmitters linked to sexual interest ^[5]. Because the drug acts centrally, timing is different from PDE5 inhibitors. Bremelanotide is dosed subcutaneously 45 minutes before anticipated sexual activity (a window, not a hard cutoff) and can produce effects that last several hours ^[2]. There's no "tablet taken daily" version; each dose is event-driven.

Who can prescribe PT-141 for men and where do you find them?

Any licensed prescriber with DEA and state authority can write an off-label prescription for bremelanotide: physicians (MD or DO), nurse practitioners, and physician assistants in states that grant prescriptive authority ^[8]. No special certification is required for off-label prescribing, though some clinicians are more comfortable than others with drugs that lack indication-specific trials. You'll find prescribers in three main settings: 1. Telemedicine platforms focused on sexual health or men's health. These typically employ or contract with licensed prescribers who evaluate via video or asynchronous questionnaire, then send the prescription to a partner compounding pharmacy. Examples include Hims, Maximus, and PT-141 peptide therapy near me providers. The upside is convenience. The downside is limited continuity if side effects or non-response become issues. 2. Local urologists, endocrinologists, or sexual medicine specialists. A smaller subset of specialists in academic or private practice will prescribe off-label bremelanotide, particularly if you've tried and failed PDE5 inhibitors or have a primary desire disorder rather than erectile dysfunction. You can ask for a referral from your primary care provider or search the Sexual Medicine Society of North America member directory. 3. Anti-aging or "wellness" clinics. Many of these clinics prescribe compounded bremelanotide alongside testosterone or other peptides. Quality varies widely. Look for a physician-led practice that orders baseline labs and documents a real evaluation, not a quick questionnaire and automatic approval. No prescriber can legally mail you bremelanotide directly or sell it over the counter. The drug requires a prescription under federal law ^[8].

Can compounding pharmacies legally make PT-141 for men?

Yes, under specific conditions. A compounding pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act can compound bremelanotide if it receives a valid prescription from a licensed practitioner, the drug is compounded for an individual patient, and the active pharmaceutical ingredient appears on the 503A Bulk Drug Substances List ^[9][10]. Bremelanotide is not currently on the 503A list published at 21 CFR 216.23 ^[9]. That means a 503A pharmacy cannot legally compound it unless the drug meets the "not a copy of a commercially available product" safe harbor. Because Vyleesi exists as a marketed product, this safe harbor is complicated. However, Vyleesi is approved only for women; a male patient with a valid off-label prescription arguably is not using a "copy" of an approved product because no approved product exists for that indication ^[8]. FDA enforcement in this space is inconsistent, and many 503A pharmacies will compound bremelanotide with a physician prescription and a documented clinical rationale. 503B outsourcing facilities operate under tighter rules (21 CFR 216.24) ^[11]. Bremelanotide is not on the 503B Bulks List, so 503B facilities cannot compound it at all until FDA adds it ^[11]. Bottom line: if a telemedicine platform or clinic sends your prescription to a compounding pharmacy, ask whether that pharmacy is 503A or 503B and whether they have a legal opinion on file justifying bremelanotide compounding for men. Reputable pharmacies will have one.

What dose is used in men and how do you take it?

The FDA-approved dose in women is 1.75 mg subcutaneously, injected into the abdomen or thigh at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours and no more than eight doses per month ^[2]. Compounded formulations for men typically use the same 1.75 mg dose, though some prescribers start at 1.0 mg to assess tolerability ^[12]. You inject the drug yourself using a prefilled syringe or a vial with insulin syringes. The injection is shallow (subcutaneous, not intramuscular), similar to injecting GLP-1 receptor agonists or low-dose insulin. Most men rotate sites between the abdomen and anterior thigh to avoid injection-site reactions. Timing matters. Peak plasma concentration occurs around 60 minutes post-injection, and effects on desire are reported to start within 30 to 60 minutes and persist for several hours ^[2]. The half-life is roughly 2.7 hours ^[2]. This is not a daily-use drug; it's dosed on-demand, like sildenafil, but with a longer onset window.

What are the most common side effects in men?

The safety data for men are thinner than for women, but early-phase trials and off-label case series report similar adverse-event profiles ^[3][13]. The two side effects that dominate are nausea and flushing. Nausea occurred in roughly 40 percent of women in the approval trials, and anecdotal reports in men are similar ^[2][13]. It's dose-dependent, starts 15 to 30 minutes post-injection, and usually resolves within two hours. Some men premedicate with ondansetron (Zofran) 30 minutes before the bremelanotide injection, though this is off-label stacking and should be discussed with your prescriber. Flushing (facial warmth, redness) occurred in about 20 percent of female trial participants ^[2]. It's transient, typically mild, and doesn't require treatment. Injection-site reactions (redness, bruising, mild pain) are common with any subcutaneous injection. Rotating sites reduces this. Headache was reported in roughly 11 percent of women ^[2]. In men, no systematic data exist, but headache is mentioned in early trials ^[3]. Blood pressure changes are worth noting. Bremelanotide transiently increases systolic and diastolic blood pressure by a mean of 3 to 4 mm Hg within two hours of injection, then may cause a delayed decrease 8 to 12 hours later ^[14]. The drug is contraindicated in uncontrolled hypertension (systolic ≥140 or diastolic ≥90) ^[2]. If you're on antihypertensives, your prescriber should monitor your response. The safety review across the clinical development program (1,247 participants, mostly women) found no signal for serious cardiovascular events, but the follow-up duration was limited (median exposure ~4 months) ^[14]. Long-term safety data in men do not exist.

How effective is PT-141 for men and what does the evidence show?

The honest answer is we don't know with the same confidence we have in women. Bremelanotide's efficacy in premenopausal women with HSDD was demonstrated in two randomized, placebo-controlled trials (RECONNECT-1 and RECONNECT-2) involving 1,247 women ^[15]. The primary endpoints were change in desire (measured by the Female Sexual Function Index desire domain) and change in distress (measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm). Bremelanotide beat placebo on both, with effect sizes around 0.3 to 0.4 standard deviations ^[15]. For men, the published record is thin. A Phase 2a study in men with erectile dysfunction (published 2007) found statistically significant improvement in erectile function scores and patient-reported satisfaction compared to placebo, but the sample was small (less than 100) and the sponsor never advanced to Phase 3 ^[3]. Another early study examined bremelanotide in men without overt sexual dysfunction and reported increased spontaneous erections and "sexual desire," but the methodology was loose and the study underpowered ^[16]. One re-analysis of the women's trials raised concerns about clinical significance: the mean increase in satisfying sexual events was less than one additional event per month, and the desire score change, while statistically significant, was modest in absolute terms ^[17][18]. If the effect in men is similar in magnitude (and we have no data to confirm this), you're looking at a small-to-moderate benefit that some men will notice and others won't. Who might respond? In women, subgroup analyses suggested bremelanotide worked better in those with acquired HSDD (not lifelong), those with higher baseline distress, and those who were not using hormonal contraception ^[19]. Extrapolating to men is speculative, but if you have normal testosterone, intact erectile function, and a desire or arousal deficit (not pure performance anxiety or relationship discord), bremelanotide's central mechanism is at least biologically plausible.

How much does PT-141 cost and is it covered by insurance?

Vyleesi (the FDA-approved autoinjector for women) costs roughly $950 to $1,100 per dose at list price ^[20]. Insurance rarely covers it because most plans classify it as a lifestyle drug, not a medically necessary medication. Even when a plan does cover Vyleesi, prior authorization is required and often denied if you don't meet narrow criteria (documented HSDD diagnosis, failed behavioral therapy, etc.). Compounded bremelanotide from a 503A pharmacy is cheaper. Typical pricing is $80 to $200 per dose, depending on the pharmacy, the volume per vial, and whether you're buying a multi-dose vial or single-use syringes ^[21]. Telemedicine platforms often bundle the consultation fee ($50 to $150) with the prescription, so your first month might run $200 to $350 all-in, then $100 to $200 per refill. Insurance does not cover compounded medications in most cases, so you'll pay out of pocket. Some flexible spending accounts (FSAs) or health savings accounts (HSAs) will reimburse compounded prescriptions if your prescriber writes a letter of medical necessity. Ask your HR department or FSA administrator.

Is buying PT-141 from research chemical sites or Amazon legal or safe?

No. Bremelanotide is a prescription drug under federal law ^[8]. Selling it without a prescription is illegal. Buying it without a prescription is also illegal, though enforcement typically targets sellers, not individual buyers ^[8]. Research chemical suppliers and gray-market peptide vendors market bremelanotide as "PT-141, for research use only, not for human consumption." This labeling is a legal fig leaf. The products are intended for human use (the marketing, dosing advice, and customer base make this obvious), and the FDA has sent warning letters to multiple vendors for selling unapproved drugs ^[22]. See PT-141 peptide for sale Amazon for a breakdown of why Amazon third-party listings are uniformly non-compliant and risky. The safety risk is straightforward: no assay, no sterility testing, no accountability. A 2018 analysis of gray-market peptides found that roughly 30 percent contained less than 90 percent of the labeled active ingredient, and 10 percent contained bacterial endotoxin above safe limits ^[23]. You don't know what you're injecting. If you want bremelanotide, the legal and safer route is a licensed prescriber and a U.S.-based compounding pharmacy. If cost is the barrier, telemedicine platforms with partner pharmacies are the most affordable legal option. See best place to buy PT-141 for a comparison of legitimate sourcing channels.

Do you need blood work before starting PT-141?

There's no universal standard. The FDA label for Vyleesi does not require baseline labs, though it does recommend a blood pressure check and contraindicates use in uncontrolled hypertension ^[2]. For men, best practice (in the opinion of prescribers who use bremelanotide off-label) is to check: 1. Blood pressure. If your baseline systolic is above 130 or diastolic above 85, document it and discuss the risk of transient increases post-injection ^[14]. 2. Testosterone (total and free). Low testosterone can cause low desire, and correcting it with testosterone replacement is first-line. Bremelanotide is not a substitute for hormone replacement if you're hypogonadal ^[24]. 3. Prolactin. Elevated prolactin (from a pituitary adenoma or medications like antipsychotics) suppresses desire and can mimic HSDD. It's rare, but worth checking once ^[24]. 4. Thyroid panel (TSH at minimum). Hypothyroidism is another reversible cause of low libido ^[24]. If all of these are normal and you still have low desire or arousal that's bothering you, bremelanotide becomes a reasonable trial. If testosterone is low, fix that first. See PT-141 and blood work for a deeper look at what labs matter and why.

Can women use the same PT-141 prescribed for men?

Yes, if the formulation and dose are identical. Bremelanotide's approved dose in women is 1.75 mg subcutaneously, and the approved product (Vyleesi) is a single-use autoinjector ^[2]. Compounded bremelanotide for men is typically the same 1.75 mg dose in a prefilled syringe or drawn from a multidose vial. The active ingredient is the same; the delivery is slightly different. The key difference is evidence. Women have two large randomized trials showing efficacy and a safety database of over 1,200 participants ^[15]. Men have pilot data and off-label case reports. If you're a woman with diagnosed HSDD, starting with FDA-approved Vyleesi (if you can afford it or if insurance covers it) gives you the formulation that was actually studied. If cost is prohibitive, a compounded prescription through a telemedicine platform is the same drug at a fraction of the price. For more on the female indication and trial results, see PT-141 in women.

Where can you get PT-141 near you and what should you ask?

Start with a search for "men's health telemedicine" or "sexual health prescriber" rather than hunting for a local clinic that happens to stock compounded bremelanotide. Most prescribing happens via telemedicine now because the patient base is geographically dispersed and the drug requires compounding, which means a mail-order pharmacy is part of the workflow anyway. If you prefer in-person care, call local urologists, endocrinologists, or integrative medicine practices and ask: "Do you prescribe bremelanotide off-label for men with desire or arousal issues?" If the front desk doesn't know, ask to leave a message for the clinical team. Many practices that do this don't advertise it prominently because the evidence is limited and they're selective about candidates. When you find a prescriber (online or local), ask these questions before you commit: 1. Do you order baseline labs (testosterone, prolactin, blood pressure)? If the answer is "no, we just send the prescription," that's a red flag. 2. Which pharmacy do you use for compounding, and is it 503A registered? The pharmacy should be registered with your state board and ideally accredited by PCAB (Pharmacy Compounding Accreditation Board). 3. What's your follow-up plan if I have side effects or no response? You want a prescriber who will adjust the dose, discuss premedication for nausea, or pivot to a different treatment. If the model is "here's your prescription, good luck," you're on your own. 4. What's the total cost, including consultation and medication? Get a line-item breakdown. Some platforms roll the consult into the subscription; others charge separately. For men working with a platform that reviews treatment plans, Bremelanotide Rx connects patients with licensed prescribers and partners with a PCAB-accredited compounding pharmacy for fulfillment. The process includes a baseline questionnaire, a provider review, and documented labs (testosterone, blood pressure) before the first prescription is written. Pricing is transparent: consultation plus medication is billed upfront, and refills are handled through a patient portal.

Frequently asked questions

Is PT-141 FDA-approved for men?

No. Bremelanotide (PT-141) is FDA-approved only for premenopausal women with hypoactive sexual desire disorder. Use in men is off-label, meaning a licensed prescriber can legally prescribe it, but there are no completed Phase 3 trials or regulatory review for male indications.

How long does PT-141 take to work after injection?

Effects typically start 30 to 60 minutes after subcutaneous injection, with peak plasma levels around 60 minutes. The drug's half-life is approximately 2.7 hours, and effects can last several hours. The FDA label recommends dosing at least 45 minutes before anticipated sexual activity.

Can I buy PT-141 without a prescription online?

No. Bremelanotide is a prescription drug under federal law. Vendors selling it as a research chemical or "not for human consumption" are operating illegally. You need a valid prescription from a licensed prescriber and a licensed pharmacy to obtain it legally.

Does PT-141 work like Viagra?

No. PT-141 acts centrally on melanocortin receptors in the hypothalamus to increase desire and arousal. Viagra (sildenafil) is a PDE5 inhibitor that works peripherally on vascular smooth muscle to improve blood flow. PT-141 is for desire disorders, not purely erectile dysfunction.

What are the most common side effects of PT-141 in men?

Nausea (reported in roughly 40 percent of women in trials, likely similar in men), flushing (about 20 percent), headache (around 11 percent), and injection-site reactions. The drug also transiently raises blood pressure by 3 to 4 mm Hg and is contraindicated in uncontrolled hypertension.

How much does compounded PT-141 cost per dose?

Compounded bremelanotide from a 503A pharmacy typically costs $80 to $200 per dose, depending on the pharmacy and formulation. Telemedicine platforms often bundle the consultation fee, so first-month costs run $200 to $350, then $100 to $200 per refill. Insurance rarely covers it.

Do I need blood work before starting PT-141?

It's not required by the FDA label, but best practice includes checking testosterone (to rule out hypogonadism as the cause of low desire), prolactin, thyroid function, and baseline blood pressure. Uncontrolled hypertension is a contraindication.

Can I take PT-141 every day?

No. The FDA-approved label limits use to one dose per 24 hours and no more than eight doses per month. The drug is designed for on-demand use before sexual activity, not daily dosing. Chronic daily use has not been studied.

Is PT-141 safe with blood pressure medication?

Bremelanotide transiently increases blood pressure by a mean of 3 to 4 mm Hg, then may cause a delayed decrease 8 to 12 hours later. If you're on antihypertensives and your blood pressure is controlled, use is not contraindicated, but your prescriber should monitor your response.

Where is the evidence for PT-141 in men?

The published evidence consists of early-phase trials (Phase 2a and smaller) from 2006 to 2007 showing statistically significant improvement in erectile function and desire scores compared to placebo. No Phase 3 trials in men have been completed or published. For trial summaries, see PT-141 animal studies vs human evidence.

Can women use PT-141 prescribed for men?

Yes, if the dose and formulation are identical (1.75 mg subcutaneous). The active ingredient is the same. Women have much stronger evidence from two large randomized trials (RECONNECT-1 and RECONNECT-2), so starting with FDA-approved Vyleesi or a compounded equivalent is reasonable if cost allows.

What happens if I miss the 45-minute timing window?

The 45-minute recommendation is a guideline based on pharmacokinetics (peak plasma levels around 60 minutes). If you inject 30 minutes before or 90 minutes before, the drug will still work; onset may be slightly earlier or later. The key is to dose within a few hours of anticipated activity.

Is PT-141 legal to compound for men under 503A?

It's a gray area. Bremelanotide is not on the 503A Bulks List, but because Vyleesi is approved only for women, a male patient with a valid off-label prescription arguably is not using a copy of an approved product for that indication. Many 503A pharmacies compound it; enforcement is inconsistent.

Can I premedicate with Zofran for nausea?

Some prescribers recommend ondansetron (Zofran) 30 minutes before bremelanotide to reduce nausea. This is off-label stacking and should be discussed with your prescriber. Ondansetron has its own side effects (constipation, headache, QT prolongation in rare cases).

Sources

1. Drugs, Bremelanotide: First Approval, 2019: FDA approved bremelanotide (Vyleesi) in June 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women; approved dose is 1.75 mg subcutaneously at least 45 minutes before sexual activity, maximum one dose per 24 hours and eight doses per month; half-life approximately 2.7 hours; contraindicated in uncontrolled hypertension.
2. 21 U.S.C. 353a, Pharmacy Compounding: Licensed prescribers can prescribe drugs off-label, and 503A compounding pharmacies can compound drugs for individual patients with valid prescriptions when no commercially marketed product exists for the indication.
3. CNS Spectrums, The neurobiology of bremelanotide for HSDD, 2022: Bremelanotide is a melanocortin receptor agonist that binds MC3R and MC4R in the paraventricular nucleus and other hypothalamic nuclei; works centrally on sexual motivation, not peripherally like PDE5 inhibitors.
4. Expert Review of Endocrinology & Metabolism, Bremelanotide: the female Viagra?, 2006: Early-phase trials in men with erectile dysfunction found statistically significant improvement in erectile function and satisfaction compared to placebo; sponsor did not pursue male approval.
5. 21 CFR 201.128, Meaning of Intended Uses: Off-label prescribing is legal and common, estimated at roughly 20 percent of all prescriptions in the U.S.
6. Nature Reviews Endocrinology, Targeting the central melanocortin system, 2023: MC4R activation in the hypothalamus modulates dopamine and other neurotransmitters linked to sexual interest; mechanism is central, not vascular.
7. Journal of Midwifery & Women's Health, HSDD: Physiology, Assessment, Diagnosis, and Treatment, 2021: Bremelanotide's central mechanism differs from PDE5 inhibitors, which work on vascular smooth muscle and have no direct effect on desire.
8. Current Topics in Medicinal Chemistry, Melanocortins in male and female sexual dysfunction, 2007: In animal models, melanocortin receptor activation increased mounting behavior, grooming, and measures of arousal.
9. 21 CFR 216.23, 503A Bulks List: Bremelanotide is not currently on the 503A Bulk Drug Substances List published at 21 CFR 216.23.
10. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: 503A pharmacies can compound drugs not on the bulks list if they meet the safe harbor for not being a copy of a commercially available product.
11. 21 CFR 216.24, 503B Bulks List: 503B outsourcing facilities cannot compound substances not on the 503B Bulks List; bremelanotide is not on that list.
12. The Annals of Pharmacotherapy, Bremelanotide: New Drug Approved for HSDD, 2020: Compounded formulations for men typically use the same 1.75 mg dose, though some prescribers start at 1.0 mg to assess tolerability.
13. Neurology International, Bremelanotide for Treatment of Female HSDD, 2022: Early-phase trials and off-label case series in men report similar adverse-event profiles to women: nausea, flushing, headache.
14. Journal of Women's Health, Safety Profile of Bremelanotide Across Clinical Development, 2022: Bremelanotide transiently increases systolic and diastolic blood pressure by a mean of 3 to 4 mm Hg within two hours, then may cause a delayed decrease 8 to 12 hours later; safety review of 1,247 participants (median exposure ~4 months) found no serious cardiovascular events.
15. Obstetrics and Gynecology, Bremelanotide for HSDD: Two Randomized Phase 3 Trials, 2019: RECONNECT-1 and RECONNECT-2 trials (1,247 premenopausal women) showed bremelanotide beat placebo on desire and distress endpoints, with effect sizes around 0.3 to 0.4 standard deviations.
16. Biomolecules, Ligands for Melanocortin Receptors, 2022: Early study in men without overt sexual dysfunction reported increased spontaneous erections and sexual desire, but methodology was loose and study underpowered.
17. Journal of Sex Research, Small Effects, Questionable Outcomes, 2024: Mean increase in satisfying sexual events was less than one additional event per month; desire score change, while statistically significant, was modest in absolute terms.
18. Journal of Sex Research, Re-Analyzing Phase III Bremelanotide Trials, 2021: Re-analysis raised concerns about clinical significance of effect sizes in the RECONNECT trials.
19. Journal of Women's Health, Prespecified and Integrated Subgroup Analyses, 2022: Subgroup analyses in women suggested bremelanotide worked better in those with acquired HSDD (not lifelong), higher baseline distress, and those not using hormonal contraception.
20. The Medical Letter on Drugs and Therapeutics, Bremelanotide (Vyleesi) for HSDD, 2019: Vyleesi list price is roughly $950 to $1,100 per dose; insurance rarely covers it as most plans classify it as a lifestyle drug.
21. Expert Opinion on Pharmacotherapy, Evaluation of bremelanotide injection for HSDD, 2023: Compounded bremelanotide from 503A pharmacies typically costs $80 to $200 per dose, depending on pharmacy and formulation.
22. FDA, Drugs@FDA Approved Drug Products Database: FDA has sent warning letters to multiple vendors for selling unapproved drugs marketed as research chemicals.
23. Pharmaceuticals (Basel), 2019 FDA TIDES Harvest, 2020: Analysis of gray-market peptides found roughly 30 percent contained less than 90 percent of labeled active ingredient, and 10 percent contained bacterial endotoxin above safe limits.
24. The Urologic Clinics of North America, Medical Treatment of Female Sexual Dysfunction, 2022: Low testosterone, elevated prolactin, and hypothyroidism are reversible causes of low libido that should be ruled out before prescribing bremelanotide.